City of Hope

www.cityofhope.org

 

ASH 2022 Conference Coverage
A

ASH 2022 NX-2127-001, a First-in-Human Trial of NX-2127, a BTK-Targeted Protein Degrader, in Patients With R/R CLL and B-Cell Malignancies

By ASH 2022 Conference Coverage FEATURING Alexey Danilov
By ASH 2022 Conference Coverage FEATURING Alexey Danilov
29 views
January 11, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Leukemia
08:26
City of Hope

Primary Analysis of TRANSCEND CLL 004 - Liso-Cel in R/R CLL/SLL

Feat. T. Siddiqi
08:35
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Primary Analysis of the Phase 1/2, Single-Arm, Multicenter…

Feat. T. Siddiqi
06:23
City of Hope

TKI-BiTE Combo in Ph+ALL: Integrating Expert Opinion With Clinical T…

Feat. I. Aldoss
06:57
ASH 2022 Conference Coverage

ASH 2022 NX-2127-001, a First-in-Human Trial of NX-2127, a BTK-Targe…

Feat. A. Danilov
06:20
ASH 2022 Conference Coverage

Consolidation With Allogeneic HCT Improved Survival Outcomes of Adul…

Feat. I. Aldoss
09:33
City of Hope

Assessing Comorbidities in CLL

Feat. A. Danilov
18:28
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on Optimizing Lymphodepletion Prior to CAR-T Therap…

Feat. E. Budde
33:39
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on CAR-T for R/R AML: What Are the Current Limitati…

Feat. E. Budde
25:04
City of Hope

How to Sequence Novel Agents in CLL

Feat. T. Siddiqi